176 related articles for article (PubMed ID: 29879943)
1. Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates.
Ginindza TG; Sartorius B
BMC Cancer; 2018 Jun; 18(1):639. PubMed ID: 29879943
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland.
Ginindza TG; Dlamini X; Almonte M; Herrero R; Jolly PE; Tsoka-Gwegweni JM; Weiderpass E; Broutet N; Sartorius B
PLoS One; 2017; 12(1):e0170189. PubMed ID: 28114325
[TBL] [Abstract][Full Text] [Related]
3. Using HPV prevalence to predict cervical cancer incidence.
Sharma M; Bruni L; Diaz M; Castellsagué X; de Sanjosé S; Bosch FX; Kim JJ
Int J Cancer; 2013 Apr; 132(8):1895-900. PubMed ID: 22965284
[TBL] [Abstract][Full Text] [Related]
4. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
6. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis.
Burger EA; de Kok IMCM; Groene E; Killen J; Canfell K; Kulasingam S; Kuntz KM; Matthijsse S; Regan C; Simms KT; Smith MA; Sy S; Alarid-Escudero F; Vaidyanathan V; van Ballegooijen M; Kim JJ
J Natl Cancer Inst; 2020 Sep; 112(9):955-963. PubMed ID: 31821501
[TBL] [Abstract][Full Text] [Related]
8. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
9. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
10. Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer.
Burger EA; Kim JJ; Sy S; Castle PE
Clin Infect Dis; 2017 Sep; 65(6):893-899. PubMed ID: 28531261
[TBL] [Abstract][Full Text] [Related]
11. Global burden of human papillomavirus and related diseases.
Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
[TBL] [Abstract][Full Text] [Related]
12. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.
Rao DW; Bayer CJ; Liu G; Chikandiwa A; Sharma M; Hathaway CL; Tan N; Mugo N; Barnabas RV
J Int AIDS Soc; 2022 Oct; 25(10):e26021. PubMed ID: 36225139
[TBL] [Abstract][Full Text] [Related]
13. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
17. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
18. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
19. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
20. The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study.
Akullian A; Morrison M; Garnett GP; Mnisi Z; Lukhele N; Bridenbecker D; Bershteyn A
Lancet HIV; 2020 May; 7(5):e348-e358. PubMed ID: 32061317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
